Search Results

You are looking at 1 - 10 of 39 items for :

Clear All
Open access

L Ahlkvist, K Brown and B Ahrén

experiments that the incretin effect, i.e., the augmented insulin secretion seen after oral vs i.v. glucose, is increased in insulin-resistant mice (3) and that the β-cell responsiveness to intravenous glucagon-like peptide-1 (GLP1) is augmented (3, 4

Open access

Dorte Glintborg, Hanne Mumm, Jens Juul Holst and Marianne Andersen

). Incretin hormones are released after meal ingestion and account for up to 70% of postprandial insulin secretion ( 3 ). Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide are the most important incretin hormones. GLP-1 secretion is impaired

Open access

C L Bodinham, L Smith, E L Thomas, J D Bell, J R Swann, A Costabile, D Russell-Jones, A M Umpleby and M D Robertson

investigated. Animal studies have consistently shown that RS improves glucose and insulin metabolism through increased postprandial GLP1 secretion due to stimulation of the colonic enteroendocrine cells (8, 9) . This can result in improved insulin secretion

Open access

David P Sonne, Asger Lund, Jens Faber, Jens J Holst, Tina Vilsbøll and Filip K Knop

i) whether i.v. glucose per se could affect thyroid function parameters and ii) whether any changes could be elicited by infusion of the gastrointestinal hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP1

Open access

Jeppe Skov, Jens Juul Holst, Jens Peter Gøtze, Jørgen Frøkiær and Jens Sandahl Christiansen

Introduction Glucagon-like peptide-1 (GLP1) is a gut-derived incretin hormone with multiple actions in addition to control of glucose homeostasis (1) . Synthetic GLP1 receptor (GLP1R) agonists lower blood pressure in patients with type 2 diabetes

Open access

Nicolai J Wewer Albrechtsen, Monika J Bak, Bolette Hartmann, Louise Wulff Christensen, Rune E Kuhre, Carolyn F Deacon and Jens J Holst

Introduction Glucagon-like peptide 1 (GLP-1) and glucagon arise from differential processing of the glucagon precursor, proglucagon (PG) (1) . Both peptides are important for normal glucose homeostasis, which focused interest on their potential

Open access

Jukka Koffert, Henri Honka, Jarmo Teuho, Saila Kauhanen, Saija Hurme, Riitta Parkkola, Vesa Oikonen, Andrea Mari, Andreas Lindqvist, Nils Wierup, Leif Groop and Pirjo Nuutila

circulation. When Kogire and co-workers ( 10 ) injected GIP to healthy dogs, they observed increased BF in SMA but not in CA, suggesting that GIP contributes to the redistribution of BF after a meal. Similar results have been reported for GLP-1 ( 11 ). However

Open access

Shin-ya Ueda, Hidehiro Nakahara, Eriko Kawai, Tatsuya Usui, Shintaro Tsuji and Tadayoshi Miyamoto

glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and ghrelin ( 2 ). The effects of exercise on these hormones have been investigated extensively over the past decade ( 3 , 4 ). Previous findings suggested that the concentrations of anorexigenic hormones

Open access

Lili Liu, Zhuo Shao, Ying Xia, Jiabi Qin, Yang Xiao, Zhiguang Zhou and Zubing Mei

. Incretin-based drugs, including glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase 4 (DPP-4) inhibitors, may offer an opportunity to avoid these side effects. Theoretically, GLP-1 RAs are structurally and functionally similar to

Open access

Agnieszka Kosowska, Enrique Gallego-Colon, Wojciech Garczorz, Agnieszka Kłych-Ratuszny, Mohammad Reza F Aghdam, Michał Woz´niak, Andrzej Witek, Agnieszka Wróblewska-Czech, Anna Cygal, Jerzy Wojnar and Tomasz Francuz

mechanism of action of incretin mimetic drugs is through the binding to glucagon-like peptide-1 receptor (GLP-1R) in pancreatic beta cells stimulating insulin secretion. The two most important natural incretin hormones are glucagon-like peptide-1 (GLP-1) and